{"date":"2026-01-05","count":13,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6945-2026-01-05-1830-19k778u","company_id":"6945","company":"圓祥生技","market":"上櫃","industry":"生技醫療","date":"2026-01-05","time":"18:30:45","subject":"公告本公司董事會通過與天士生物醫藥股份有限公司簽訂AP505產品補充協議案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：圓祥生技（6945），2026-01-05 18:30，「公告本公司董事會通過與天士生物醫藥股份有限公司簽訂AP505產品補充協議案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6945-2026-01-05-1830-1rso2n3","company_id":"6945","company":"圓祥生技","market":"上櫃","industry":"生技醫療","date":"2026-01-05","time":"18:30:04","subject":"公告本公司董事會通過與某美國投資銀行簽署AP505商務顧問合作協議案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：圓祥生技（6945），2026-01-05 18:30，「公告本公司董事會通過與某美國投資銀行簽署AP505商務顧問合作協議案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3164-2026-01-05-1717-ac89kl","company_id":"3164","company":"景岳","market":"上市","industry":"生技醫療","date":"2026-01-05","time":"17:17:21","subject":"公告本公司申請股票上櫃轉上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2026-01-05","cite_as":"公開資訊觀測站重大訊息：景岳（3164），2026-01-05 17:17，「公告本公司申請股票上櫃轉上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4743-2026-01-05-1711-37n9di","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2026-01-05","time":"17:11:13","subject":"公告本公司Bonvadis外用乳膏，取得埃及EDA核准完全傷口適應症之醫材上市許可","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合一（4743），2026-01-05 17:11，「公告本公司Bonvadis外用乳膏，取得埃及EDA核准完全傷口適應症之醫材上市許可」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2026-01-05-1653-1v75xhv","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-01-05","time":"16:53:04","subject":"公告本公司114年第一次私募普通股收足股款暨增資基準日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-01-05 16:53，「公告本公司114年第一次私募普通股收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6934-2026-01-05-1634-18ece9a","company_id":"6934","company":"心誠鎂","market":"上市","industry":"生技醫療","date":"2026-01-05","time":"16:34:15","subject":"本公司將於115年1月9日召開上市前業績發表會。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：心誠鎂（6934），2026-01-05 16:34，「本公司將於115年1月9日召開上市前業績發表會。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6733-2026-01-05-1632-pyh1o2","company_id":"6733","company":"博晟生醫","market":"上櫃","industry":"生技醫療","date":"2026-01-05","time":"16:32:30","subject":"公告本公司RevoCart產品專利「軟骨用植入物及其相關裝置與方法」獲得美國專利及商標局專利核准審定","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：博晟生醫（6733），2026-01-05 16:32，「公告本公司RevoCart產品專利「軟骨用植入物及其相關裝置與方法」獲得美國專利及商標局專利核准審定」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4114-2026-01-05-1625-108c6ty","company_id":"4114","company":"健喬","market":"上櫃","industry":"生技醫療","date":"2026-01-05","time":"16:25:06","subject":"本公司董事會通過簽訂獨家授權合作協議(補充114/11/11重訊)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：健喬（4114），2026-01-05 16:25，「本公司董事會通過簽訂獨家授權合作協議(補充114/11/11重訊)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4172-2026-01-05-1544-lrzu3i","company_id":"4172","company":"因華","market":"興櫃","industry":"生技醫療","date":"2026-01-05","time":"15:44:11","subject":"公告本公司開發中新藥 D07001（GemOral）人體臨床第二期試驗計畫（Inno-GO-08）已向 TFDA 送件申請（適應症：晚期非小細胞肺癌〔NSCLC〕/胰臟癌）","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：因華（4172），2026-01-05 15:44，「公告本公司開發中新藥 D07001（GemOral）人體臨床第二期試驗計畫（Inno-GO-08）已向 TFDA 送件申」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7829-2026-01-05-1537-arkidq","company_id":"7829","company":"思捷優達-KY","market":"興櫃","industry":"生技醫療","date":"2026-01-05","time":"15:37:40","subject":"公告本公司114年第一次現金增資收足股款暨增資基準日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：思捷優達-KY（7829），2026-01-05 15:37，「公告本公司114年第一次現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6659-2026-01-05-1435-7tf0ag","company_id":"6659","company":"天明製藥","market":"興櫃","industry":"生技醫療","date":"2026-01-05","time":"14:35:14","subject":"本公司依「特定醫療技術檢查檢驗醫療儀器施行或使用管理辦法」申請「自體免疫細胞(CIK)治療實體癌第四期」細胞治療技術之細胞製備場所一案，獲衛福部認可。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：天明製藥（6659），2026-01-05 14:35，「本公司依「特定醫療技術檢查檢驗醫療儀器施行或使用管理辦法」申請「自體免疫細胞(CIK)治療實體癌第四期」細胞治療技術之細」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7878-2026-01-05-1104-13bhjjk","company_id":"7878","company":"藥祇","market":"興櫃","industry":"生技醫療","date":"2026-01-05","time":"11:04:06","subject":"本公司受邀參加凱基證券之法人座談會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：藥祇（7878），2026-01-05 11:04，「本公司受邀參加凱基證券之法人座談會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6612-2026-01-05-0804-y976dj","company_id":"6612","company":"奈米醫材","market":"上櫃","industry":"生技醫療","date":"2026-01-05","time":"08:04:17","subject":"代子公司 MILLENNIUM BIOMEDICAL INC.公告- 總經理異動公告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：奈米醫材（6612），2026-01-05 08:04，「代子公司 MILLENNIUM BIOMEDICAL INC.公告- 總經理異動公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}